Wedbush reiterates Larimar Therapeutics stock rating at Outperform
AI Summary
Wedbush reiterated its Outperform rating on Larimar Therapeutics stock. The headline does not provide a price target or further details about the analyst's view.
Related Articles
Vitol’s Venezuela Oil Windfall Traced to Trader’s Ties to JD Vance
Oilprice.com —
Superior Plus Corp. (SPB:CA) Q3 2026 Earnings Call Transcript
Seeking Alpha —
Anterix Inc. (ATEX) Q2 2027 Earnings Call Transcript
Seeking Alpha —
Nvidia's Biggest Threat Is AI That Needs Fewer Chips
Seeking Alpha —
Don't Fight The Momentum: Roivant Has Big Expectations, But Real Pipeline Momentum
Seeking Alpha —
NextEra Energy: Forgotten AI Winner After Democratic Sweep
Seeking Alpha —